S&P Futures
3,998.00 +15.00 (+0.38%) Dow Futures
32,558.00 +102.00 (+0.31%) Nasdaq Futures
12,723.00 +34.50 (+0.27%) Russell 2000 Futures
1,774.20 +13.50 (+0.77%) Crude Oil
67.99 +0.35 (+0.52%) Gold
1,971.00 -11.80 (-0.60%)
Arrowhead Pharmaceuticals, Inc. (ARWR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 24.30 |
| Open | 24.39 |
| Bid | 0.00 x 1200 |
| Ask | 28.55 x 800 |
| Day's Range | 24.33 - 25.85 |
| 52 Week Range | 23.09 - 51.11 |
| Volume | |
| Avg. Volume | 1,120,830 |
| Market Cap | 2.714B |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.51 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 60.54 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ARWR
Related Research
- Arrowhead Pharmaceuticals, Inc.ARWR: Lowering target price to $26.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $26.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.RatingFair ValueEconomic Moat6 days agoArgus Research
- Business Wire
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
PASADENA, Calif., March 20, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union.
- Simply Wall St.
Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 329% gain
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders might be concerned after seeing the share price drop 12...
- Business Wire
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
PASADENA, Calif., March 03, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the respiratory/infections panel discussion on March 8, 2023, at 10:30 a.m. ET at the Cowen 43rd Annual Health Care Conference being held in Boston.
